AU2019269590A1 - Mucus-penetrating peptides, delivery vehicles and methods of therapy - Google Patents

Mucus-penetrating peptides, delivery vehicles and methods of therapy Download PDF

Info

Publication number
AU2019269590A1
AU2019269590A1 AU2019269590A AU2019269590A AU2019269590A1 AU 2019269590 A1 AU2019269590 A1 AU 2019269590A1 AU 2019269590 A AU2019269590 A AU 2019269590A AU 2019269590 A AU2019269590 A AU 2019269590A AU 2019269590 A1 AU2019269590 A1 AU 2019269590A1
Authority
AU
Australia
Prior art keywords
peptide
mucus
delivery vehicle
composition
penetrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019269590A
Other languages
English (en)
Inventor
Mubhij AHMAD
Cassandra CALLMANN
Timothy Paul Day
Ismail Hafez
Xixi ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of AU2019269590A1 publication Critical patent/AU2019269590A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019269590A 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy Abandoned AU2019269590A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671709P 2018-05-15 2018-05-15
US62/671,709 2018-05-15
PCT/US2019/032484 WO2019222400A2 (en) 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy

Publications (1)

Publication Number Publication Date
AU2019269590A1 true AU2019269590A1 (en) 2020-12-03

Family

ID=68540758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019269590A Abandoned AU2019269590A1 (en) 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy

Country Status (7)

Country Link
US (1) US20210177982A1 (https=)
EP (1) EP3796892A2 (https=)
JP (1) JP2021523912A (https=)
CN (1) CN112367974A (https=)
AU (1) AU2019269590A1 (https=)
CA (1) CA3100020A1 (https=)
WO (1) WO2019222400A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176111A (en) 1876-04-11 Improvement in car-couplings
EP2253326B1 (en) * 2008-02-28 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2863632C (en) * 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013256064B2 (en) * 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR101669203B1 (ko) * 2014-06-18 2016-10-25 한국과학기술연구원 신규 세포투과성 펩타이드 및 이의 용도
WO2018013907A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
US11090391B2 (en) * 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Also Published As

Publication number Publication date
EP3796892A2 (en) 2021-03-31
JP2021523912A (ja) 2021-09-09
WO2019222400A3 (en) 2020-02-13
CA3100020A1 (en) 2019-11-21
CN112367974A (zh) 2021-02-12
WO2019222400A2 (en) 2019-11-21
US20210177982A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2020290516B2 (en) Compositions and methods for biological delivery vehicles
Mollé et al. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US11904057B2 (en) Nanoparticle-hydrogel composite for nucleic acid molecule delivery
US20120258104A1 (en) Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
Berger et al. Optimizing pDNA lipo-polyplexes: a balancing act between stability and cargo release
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
US20190351071A1 (en) Structures and methods for gene therapy
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
JP2019533645A (ja) 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
US9976142B2 (en) Targeting molecule and a use thereof
Ding et al. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1
Hall et al. Peptide/lipid-associated nucleic acids (PLANAs) as a multicomponent siRNA delivery system
CA3205059A1 (en) Biological delivery systems
Geng et al. Emerging landscape of cell-penetrating peptide-mediated organelle restoration and replacement
US12036282B2 (en) Liposomal system for drug delivery
US11890352B2 (en) Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
Fu et al. Virus-inspired lipopeptide-derived nucleic acid delivery to cartilage for osteoarthritis therapy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period